Let’s glance at the details Why Evelo Biosciences, Inc. (EVLO) shares surged dramatically in ‎the AH trading

ASTR Stock
ASTR Stock

After-hours trading on Friday, Evelo Biosciences, Inc. (Nasdaq: EVLO), the stock plunged -11/56% to $10.25. It’s not clear what happened that caused the share price to fall, and investors may want to take that as a warning sign.

A clinical-stage biotechnology company creating new oral medications with systemic effects prioritizes EDP1908 as its lead clinical candidate in oncology.

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


The Company said that it would cease patient recruitment for Phase 1/2 clinical trial of EDP1503 and finalize the study.

Read More

It revealed on additional interim clinical data from EDP1503, treated with pembrolizumab in TNBC patients with its Phase 1/2 open study, were presented in a poster session at the San Antonio Breast Cancer Symposium (SABCS) 2020 Virtual Meeting. In the 12 patients who received EDP1503 at a higher dose, as of a cutoff date of October 30, 2020, the response rate was 17 percent, with a disease control rate of 25%.

It suggests that the small intestinal axis, SINTAXTM, can be targeted using oral, gut-restricted medicines.


Please enter your comment!
Please enter your name here